- EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
If one of the two were to successfully acquire the company, it would get access to Zejula, a PARP inhibitor approved to treat women with ovarian cancer.
Plus more from the biotechnology world on Wednesday, June 7.
The magnetic tape cartridges in the company's products will be under review.
The cybersecurity firm deemed it 'highly likely' that a group of hackers working with North Korea was behind the attack.